From genome to aetiology in a multifactorial disease, type 1 diabetes

BioEssays

Volumn 21, Issue 2, 1999, Pages 164-174

  Todd, John A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ALLELE; ANIMAL; AUTOIMMUNITY; CHROMOSOME MAP; CONGENIC STRAIN; GENETICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; REVIEW; VARIABLE NUMBER OF TANDEM REPEAT;

ALLELES; ANIMALS; ANIMALS, CONGENIC; AUTOIMMUNITY; CHROMOSOME MAPPING; DIABETES MELLITUS, TYPE 1; HUMANS; INTERLEUKIN-2; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MINISATELLITE REPEATS;

EID: 0033082240     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.0.CO;2-4     Document Type: Review

References (106)

1. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996;85:311-318.
2. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995;13:179-200.
3. Todd JA. A protective role of the environment in the development of type 1 diabetes? Diabetic Med 1991;8:906-910.
4. Gardner SG, et al. Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region time trend analysis. BMJ 1997;315:713-717.
5. Gibbon C, Smith T, Egger P, Betts P, Phillips D. Early infection and subsequent insulin dependent diabetes. Arch Dis Child 1997;77:384-385.
6. Cucca F, Todd JA. HLA susceptibility to type 1 diabetes methods and mechanisms. In: Browning MJ, McMichael AJ, editors. HLA/MHC: genes, molecules and function. Oxford: βIOS Scientific Publishers; 1996. p 383-406.
7. Thorsby E, Undlien D. The HLA associated predisposition to type 1 diabetes and other autoimmune dissases. J Pediatr Endocrinol Metab 1996;9:75-88.
8. She J-X. Susceptibility to type 1 diabetes: HLA-DQ and DR revisited. Immunol Today 1996;17:323-329.
9. Janeway JCA, Travers P. Immunobiology: the immune system in health and disease. Current Biology Ltd/Garland Publishing Inc London/New York. 1997.
10. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996;85: 291-297.
11. Saoudi A, Seddon B, Heath V, Fowell D, Mason D. The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset. Immunol Rev 1996;149:195-216.
12. + T cells. J Exp Med 1997;186:239-245.
13. Yui MA, et al. 1996;Production of congenic mouse strains carrying NOD-derived diabetogenic genetic intervals: an approach for the genetic dissection of complex traits. Mamm Genome 7:331-334.
14. Lyons PA, Wicker LS. Localising quantitative trait loci in the NOD mouse model of type 1 diabetes. In: Theofilopoulos A, editor. Genetics of autoimmunity. Current directions in autoimmunity. in press Basel: S Karger; 1998.
15. Wicker LS, et al. 1994;Resistance alleles at two non-major histocompatibility complex-linked insulin-dependent diabetes loci on chromosome 3 Idd3 and Idd10, protect nonobese diabetic mice from diabetes. J Exp Med 180;170-1713.
16. Livingstone A, Edwards CT, Shizuru JA, Fathman CG. Genetic analysis of diabetes in the nonobese diabetic mouse I. MHC and T cell receptor β gene expression. J Immunol 1991;146:529-534.
17. Ikegami H, et al. Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J Clin Invest 1995;96:1936-1942.
18. Podolin PL, et al. Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3. Mamm Genome 1998;9:283-286.
19. Damotte D, et al. 1997;Analysis of susceptibility of NOD mice to spontaneous and experimentally induced thyroiditis. Eur J Immunol 27:2854-2862.
20. Undlien DE, et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 1997;46:143-149.
21. Todd JA, Bell JI, McDevitt HO, HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329:599-604.
22. Reizis B, Eisenstein M, Mor F, Cohen IR. The peptide-binding strategy of the MHC class III-A molecules. Immunol Today 1998;19:212-216.
23. Antoniou AN, Elliot J, Rosmarakis E, Dyson PJ. MHC class Ab diabetogenic residue residue 57 Asp/non-Asp dimorphism influences T-cell recognition and selection. Immunogenetics 1998;47:218-225.
24. Bohme J, Brenden N, Rietz C, Pilstrom B. Dominant disease protection in MHC-transgenic NOD mice. More than one mechanism? Immunologist 1995;3/2:45-50.
25. Schmidt D, Verdaguer J, Averill N, Santamaria P. A mechanism for the major histocompatibility complex-linked resistance to autoimmumty. J Exp Med 1997;186:1059-1075.
26. Gray DWR. Mapr histocompatibility complex-based supression: a mechanism for T cell control. Med Hypoth 1998;50:289-302.
27. + thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 1997;6:401-410.
28. Singer SM, Tisch R, Yang X-D, Liblau R, McDevitt HO. Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes 1998;47: 1570-1577.
29. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998;280:243-248.
30. + regulatory T cells in the non-obese diabetic male mouse. Diabetologia 1994;37:337-343.
31. McKeever U, et al. Adoptive transfer of autoimmune diabetes and thyroiditis to athymic rats. Proc Natl Acad Sci USA 1990;87:7618-7622.
32. Hemmer B, et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997;185:1651-1659.
33. Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991;65:319-331.
34. Baum H, Davies H, Peakman M. Molecular mimicry in the MHC: hidden clues to autoimmunity? Immunol Today 1996;17:64-70.
35. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
36. Van Parijs L, Peterson DA, Abbas AK. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998;8:265-274.
37. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33:176-183.
38. Bennett ST, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nature Genet 1995;9:284-292.
39. Julier C, et al. Multiple DNA variant association analysis: application to the insulin gene region in type 1 diabetes. Am J Hum Genet 1994;55: 1247-1254.
40. Owerbach D, Gabbay K. Localisation of a Type 1 diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. Diabetes 1993;42:1708-1714.
41. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996;30:343-370.
42. Bennett ST, et al. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity ot untransmitted paternal allele. Nature Genet 1997;17:350-352.
43. Jolicoeur C, Hanahan D, Smith KM. T-cell tolerance toward a transgenic β-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc Natl Acad Sci USA 1994;91:6707-6711.
44. Heath VL, et al. The role of the thymus in the control of autoimmunity. J Autoimmun 1996;9:241-246.
45. Pugliese A, et al. The insulin gene is transcribed in the human thymus and transcriptional levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nature Genet 1997;15:293-297.
46. Vafiadis P, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nature Genet 1997;15:289-292.
47. Antonia SJ, Geiger T, Miller J, Flavell RA. Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. Int Immunol 1994;7:715-725.
48. Posselt AM, Barker CF, Friedman AL, Naji A. Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth. Science 1992;256:1321-1324.
49. von Herrath MG, Dockter J, Nerenberg M, Gairin JE, Oldstone MB. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J Exp Med 1994;180:1901-1910.
50. Wegmann DR. The immune response to islets in experimental diabetes and insulin-dependent diabetes mellitus. Curr Opin Immunol 1996;8:860-864.
51. French MB, et al. Transgenic expression of mosue proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997;46:34-39.
52. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide. Proc Natl Acad Sci USA 1996;93:956-960.
53. Bergerot I, et al. A cholera toxid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:4610-4614.
54. Matsushita S, et al. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 1994;180:873-883.
55. Congia M, Patel S, Cope AP, De Virgiliis S, Sonderstrup-McDevitt G. The T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from the pro-hormones preproinsulin and proinsulin. Proc Natl Acad Sci USA 1998;95:3833-3838.
56. Smith KM, Olson DC, Hirose R, Hanahan D. Pancreatic gene expression in rare cells of the thymic meduall: evidence for functional contribution to T cell tolerance. Int Immunol 1997;9:1355-1365.
57. Volkmann A, Zal T, Stockinger B. Antigen-presenting cells in the thymus that can negatively select MHC class II-restricted T cells recognizing a circulating self antigen. J Immunol 1997;158:693-706.
58. Geluk A, et al. HLA-DR binding analysis of peptides from islet antigens in IDDM. 1998;47:1594-1601.
59. Gyapay G, et al. 1993-1994 Gènèthon human genetic linkage map. Nature Genet 1994;7:246-339.
60. Risch N, Ghosh S, Todd JA. Statistical evaluation of multiple locus linkage data in experimental species and relevance tohuman studies: application to murine and human IDDM. Am J Hum Genet 1993;53:702-714.
61. Denny P, et al. Mapping of the insulin-dependent diabetes locus. Idd3. to a 0.35 cM interval containing the Interleukin-2 gene. Diabetes 1997;46: 695-700.
62. Suzuki H, et al. Deregulated T cell activation and autoimmunity in mice lacking Interleukin-2 receptor beta. Science 1995;268:1472-1476.
63. Horak I, Lohler J, Ma A, Smith KA. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995;148: 35-44.
64. Hunig T, Schimpl A. The IL-2 deficiency syndrome - a lethal disease caused by abnormal lymphocyte survival. In: Durum SK, Muegge K, editors. Contemporary immunology cytokine knockouts. Totowa, NJ: Humana Press; 1998 p 1-19.
65. Robb RJ, Kutny RM, Panico M, Morris HR, Chowdhry V. Amino acid sequence and post-translational modification of human interleukin 2. Proc Natl Acad Sci USA 1984;81:6486-6490.
66. Chesnut K, She J-X, Cheng I, Muralidharan K, Wakeland EK. Characterizations of candidate genes for IDD susceptibility from the diabetes-prone NOD mouse strain. Mamm Genome 1993;4:549-554.
67. Serreze DV, Hamaguchi K, Leiter E. Immunostimulation circumvents diabetes in NOD/Ltmice. J Autoimmun 1989;2:759-776.
68. Zielasek J, et al. Interleukin-2 dependent control of disease development in spontaneously diabetic BB rats. Immunology 1990;69:209-214.
69. Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez-AC. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 1990;346:271-274.
70. Rapoport MJ, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99.
71. Dauphinee MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981;127:2483-2487.
72. Wandinger KP, Wessel K, Neustock P, Siekhaus A, Kirchner H. Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis. J Neurol Sci 1997;149:87-93.
73. Kaye WA, et al. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med 1986;315:920-924.
74. Murakawa Y, et al. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol 1985;134:187-195.
75. Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 1984;33:552-555.
76. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1997;10:371-378.
77. Ludviksson BR, Gray B, Strober W, Ehrhardt RO. Dysregulated intrathymic development in the IL-2 deficient mouse leadsto colitis-inducing thymocytes. J Immunol 1997;158:104-111.
78. Teuscher C, Wardell BB, Lunceford JK, Michael SD, Tung KSK. Aod2, the locus controlling development of atrophy in neonatal thymectomy-induced autoimmune ovarian dysgenesis, is linked to 112, Fgfb, and Idd3. J Exp Med 1996;183:195-201.
79. Asano M, Toda M, Sakguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell population. J Exp Med 1996;184:387-396.
80. Zekzer D, et al. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 1997;46:1124-1132.
81. + β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J Exp Med 1995;182: 87-97.
82. + suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996;9:331-339.
83. Taguchi O, Takahashi T. Administration of anti-interleukin-2 receptor a antibody in vivo induces localised autoimmune disease. Eur J Immunol 1996;26:1608-1612.
84. + T cells. J Exp Med 1996;183:2669-2674.
85. + T-cell subset inhibitsantigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
86. + T cell lines. J Exp Med 1997;185:101-107.
87. Ludviksson BR, Ehrhardt RO, Strober W. TGF-β production regulates the development of the 2.4.6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL2-deficient mice. J Immunol 1997;159:3622-3628.
88. Fukaura H, et al. Induction of cirulating myelin basic protein and proteolipid protein-specific transforming growth factor-β 1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98:70-77.
89. Cornall RJ, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
90. Mein CA, et al. A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nature Genet 1998;19:297-300.
91. Schwanz RH. T cell clonal anergy. Curr Opin Immunol 1997;9:351-357.
92. Reed P, et al. Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11-q11. Hum Mol Genet 1997;6: 1011-1016.
93. Ghosh S, et al. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nature Genet 1993;4:404-409.
94. Gonzalez A, et al. Genetic control of diabetes progression. Immunity 1997;7:873-883.
95. Cornall RJ, et al. Type 1 diabetes in mice is linked to the interleukin-1 receptor and Lsh/lty/Bcg genes on chromosome 1. Nature 1991;353:262-265.
96. Colucci F, Bergman M-L, Penha-Goncalves C, Cilio CM. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA 1997;94: 8670-8674.
97. Garchon H-J, Luan J-J, Eloy L, Bedossa P, Bach J-F. Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T cells to apoptosis induction. Eur J Immunol 1994;24:380-384.
98. Combadiere B, et al. Differential TCR signalling regulates apoptosis and immunopathology during antigen reponses in vivo. Immunity 1998;9:305-313.
99. Todd JA, et al. Identification of susceptibility loci for insulin-dependent diabetes mellitus by trans-racial gene mapping. Nature 1989;338:587-589.
100. Todd JA, Farrall M. Panning for gold: genome-wide scanning for linkage in type 1 diabetes. Hum Mol Genet 1996;5:1443-1448.
101. Sobell JL, Heston LL, Sommer SS. Delineation of genetic predisposition to multifactorial disease: a general approach on the threshold of feasibility. Genomics 1992;12:1-6.
102. Davies JL, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994;371:130-136.
103. Nepom BS, Nepom GT, Coleman M, Kwok WW. Critical contribution of β chain residue 57 in peptide binding ability of both HLA-DR and DQ molecules. Proc Natl Acad Sci USA 1996;93:7202-7206.
104. Degli-Esposti MA, et al. An approach to the localisation of the susceptibility genes for generalised myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 1992;35:355-364.
105. Keavney B, et al. Measured haplotype analysis of the angiotensin-1 converting enzyme (ACE) gene. Hum Mol Genet 1998;7:1745-1751.
106. Templeton AR. A cladistic analysis of phenotypic associations with haplotypes inferred from restrictionendonucleasemapping of DNA sequencing. V. Analysis of case/control sampling designs: Alzheimer's disease and the apoprotein E locus Genetics 1995;140:403-409.